Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed COO
Quarterly results
Director departure
Appointed director
CARACO PHARMACEUTICAL LABORATORIES LTD (CPD) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/14/2011 8-K Quarterly results
02/22/2011 8-K Form 8-K - Current report
01/31/2011 8-K Form 8-K - Current report
12/27/2010 8-K Form 8-K - Current report
10/29/2010 8-K Form 8-K - Current report
10/08/2010 8-K Form 8-K - Current report
09/15/2010 8-K Form 8-K - Current report
08/30/2010 8-K Unregistered Sales of Equity Securities
07/28/2010 8-K Form 8-K - Current report
07/15/2010 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Caraco Pharmaceutical Laboratories, Ltd. Receives Notice Regarding NYSE Amex Continued Listing Standards DETROIT, July 15, 2010 -- Caraco Pharmaceutical Laboratories, Ltd. announced that on July 12, 2010, NYSE Amex notified the Company that it was not in compliance with the requirement under its continued listing standards that its audit committee be comprised of three independent members. On July 9, 2010, the Company informed NYSE Amex of its non-compliance with Section 803 of NYSE Amex Company Guide following the resignation of Mr. Madhava Reddy as a director of the Company on July 6, 2010, leaving two independent directors on the Company’s audit committee. Additionally, the Company notified NYSE Amex that it intends, in conformance with NYSE Amex rules, to add another independent direct..."
07/09/2010 8-K Resignation/termination of a director
03/04/2010 8-K Form 8-K - Current report
01/29/2010 8-K Form 8-K - Current report
01/21/2010 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "First Amendment to Agreement Between Caraco Pharmaceutical Laboratories, Ltd. and Sun Pharmaceutical Industries Limited"
12/17/2009 8-K/A Resignation/termination of a director
Docs: "Response Letter (e-mail correspondence) of Georges Ugeux"
10/27/2009 8-K Quarterly results
Docs: "Amendment to Article IV, Section 1 of the Amended and Restated Bylaws of the Company",
"Amendment to Article III, Section 2 of the Amended and Restated Bylaws of the Company",
"CARACO PHARMACEUTICAL LABORATORIES, LTD. STATEMENTS OF INCOME Six Months ended September 30, Quarter ended September 30, 2009 2008 2009 2008 Net sales $ 126,445,911 $ 230,465,165 $ 78,375,895 $ 122,188,425 Cost of goods sold 118,243,578 184,879,891 75,010,528 100,186,562 Gross profit before reserve for inventory seized by FDA 8,202,333 45,585,274 3,365,367 22,001,863 Reserve for inventory seized by FDA 15,950,188 - 7,503,654 - Gross profit 45,585,274 22,001,863 Selling, general and administrative expenses 10,452,575 8,055,246 6,793,364 4,237,244 Research and development costs - other 5,592,951 11,065,940 5,581,711 Operating income prior to non-recurring income 26,464,088 12,182,908 Non-recurring income 20,000,000 - 20,000,000 - Operating income 26,464,088 10,560,533 12,182,908 Other inco..."
09/29/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations",
"Consent Decree"
09/25/2009 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Response Letter (e-mail correspondence) of Georges Ugeux"
09/23/2009 8-K Resignation/termination of a director
Docs: "Letter of resignation of Georges Ugeux"
09/15/2009 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/01/2009 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/06/2009 8-K Unregistered Sales of Equity Securities
07/29/2009 8-K Quarterly results
Docs: "Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010"
07/16/2009 8-K Entry into a Material Definitive Agreement
07/10/2009 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Caraco Pharmaceutical Laboratories, Ltd. Enters into Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro® ANDA Patent Litigation DETROIT, July 10, 2009 -- Caraco Pharmaceutical Laboratories, Ltd. announced that, as part of the settlement of the legal proceedings related to Lexapro® tablets, it entered into an Asset Purchase Agreement with Forest Laboratories, Inc. to acquire several products from Forest’ s Inwood line of business. The ANDA patent litigation settlement resolves litigation involving Caraco, Forest, Forest Holdings, Ltd., and H. Lundbeck A/S and Sun Pharmaceutical Industries Limited . Caraco is a subsidiary of Sun. Among other things, with respect to Caraco, the litigation settlement involves the following provisions: 1. Forest has agreed to prov..."
07/06/2009 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Caraco Pharmaceutical Laboratories, Ltd. Announces an Indefinite Reduction in its Workforce DETROIT, July 6, 2009 -- Caraco Pharmaceutical Laboratories, Ltd. , announced today that it is in the process of instituting an indefinite reduction in its workforce of approximately 350 employees in order to align its expenses with the current voluntary cessation of its manufacturing operations in connection with the recent action by the United States Food and Drug Administration . The timing of the resumption of manufacturing operations, in whole or in part, depends on the outcome of discussions with the FDA. This should have no effect on distributed product sales that we market in the US. The Company may recall some employees to assist us in any remedial action plan that is developed based on suc..."
05/29/2009 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Fiscal Year 2009, Updates on FDA Inspection DETROIT, May 28, 2009 -- Caraco Pharmaceutical Laboratories, Ltd. recorded net sales of $337.2 million during Fiscal 2009 compared to $350.4 million during Fiscal 2008. We earned a net pre-tax income of $29.5 million during Fiscal 2009 compared to a net pre-tax income of $42.4 million during Fiscal 2008. Daniel H. Movens, Caraco’ s Chief Executive Officer said “The net sales for fiscal years 2009 and 2008 were $337.2 and $350.4 million, respectively, reflecting a decrease of 4%. The decrease was primarily due to lower sales of our own manufactured products sales, price erosion in both manufactured and distributed product sales and on account of our voluntary product recall initiated..."
04/21/2009 8-K Other Events
03/31/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "Caraco Pharmaceutical Laboratories, Ltd. Announces a Nationwide Voluntary Recall of All Lots of Digoxin Tablets Due to Size Variability DETROIT, March 31, 2009 -- Caraco Pharmaceutical Laboratories, Ltd. , a generic pharmaceutical company, announced today that all tablets of Digoxin, USP, 0.125 mg, and Digoxin, USP, 0.25 mg, distributed prior to March 31, 2009, which are not expired and are within the expiration date of September, 2011, are being voluntarily recalled to the consumer level. The tablets are being recalled because they may differ in size and therefore could have more or less of the active ingredient, digoxin. The recalled tablets were manufactured by Caraco Pharmaceutical Laboratories, Ltd. This recall is being conducted with the knowledge of the Food and Drug Administration...."
11/03/2008 8-K Form 8-K -- Current report
10/30/2008 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Copy of the slides used in connection with Caraco’ s presentation to certain investors on October 30, 2008"
10/23/2008 8-K Quarterly results
Docs: "CARACO PHARMACEUTICAL LABORATORIES, LTD. STATEMENTS OF INCOME Six months ended September 30, Quarter ended September 30, 2008 2007 2008 2007 Net sales $ 230,465,165 $ 76,754,883 $ 122,188,425 $ 41,354,567 Cost of goods sold 184,879,891 42,871,307 100,186,562 23,338,768 Gross profit 45,585,274 33,883,576 22,001,863 18,015,799 Selling, general and administrative expenses 8,055,246 6,436,725 4,237,244 3,034,058 Research and development costs - affiliate — 5,440,000 — 5,440,000 Research and development costs - other 11,065,940 8,389,210 5,581,711 5,103,723 Operating income 26,464,088 13,617,641 12,182,908 4,438,018 Other income Interest income 420,259 886,455 142,486 419,162 Other income 420,259 886,455 142,486 419,162 Net income before income taxes 26,884,347 14,504,096 12,325,394 4,857,180 I..."
10/02/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "Caraco Pharmaceutical Laboratories, Ltd. Reaches Agreement with Labor Union"
09/17/2008 8-K Unregistered Sales of Equity Securities
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy